84888-38-0 Usage
General Description
CYSTEINE(FM)-OH is a chemical compound also known as L-cysteine. It is a non-essential amino acid that is found in various protein-containing foods such as meat, eggs, and dairy products. It plays a crucial role in the synthesis of proteins and in the formation of the antioxidant glutathione. CYSTEINE(FM)-OH is also used as a dietary supplement and as a precursor for the production of flavor enhancers such as monosodium glutamate (MSG). Additionally, it is used in the food and pharmaceutical industries as a stabilizer and flavoring agent. It is also known to have skin and hair benefits, and is used in some cosmetic formulations for its antioxidant and hydrating properties.
Check Digit Verification of cas no
The CAS Registry Mumber 84888-38-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,4,8,8 and 8 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 84888-38:
(7*8)+(6*4)+(5*8)+(4*8)+(3*8)+(2*3)+(1*8)=190
190 % 10 = 0
So 84888-38-0 is a valid CAS Registry Number.
84888-38-0Relevant articles and documents
Novel design of bicyclic β-turn dipeptides on solid-phase supports and synthesis of [3.3.0]-bicyclo[2,3]-leu-enkephalin analogues
Gu, Xuyuan,Ying, Jinfa,Agnes, Richard S.,Navratilova, Edita,Davis, Peg,Stahl, Gannon,Porreca, Frank,Yamamura, Henry I.,Hruby, Victor J.
, p. 3285 - 3288 (2007/10/03)
(Chemical Equation Presented) External bicyclic β-turn dipeptide mimetics provide an excellent design approach that can offer a rich chiral ensemble of structures with different backbone conformations. We report herein a novel design of a convergent combinatorial synthetic methodology, which is illustrated by the solid-phase synthesis of a series of [3.3.0]-bicyclo [2,3]-Leu-enkephalin analogues. The reactions were optimized and the epimeric configurations were determined by 2D NMR spectroscopy. Biological assays show that these analogues have more potent δ binding affinity and bioactivity for δ vs μ opioid receptor, which may be related to the different conformations preferred by these analogues in our modeling studies.
